Nuveen Asset Management LLC Increases Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Nuveen Asset Management LLC grew its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 795,612 shares of the company's stock after acquiring an additional 54,361 shares during the period. Nuveen Asset Management LLC owned about 1.10% of Kiniksa Pharmaceuticals worth $15,737,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. SG Americas Securities LLC purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter worth approximately $355,000. China Universal Asset Management Co. Ltd. increased its holdings in Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after acquiring an additional 1,004 shares in the last quarter. Peregrine Capital Management LLC raised its position in Kiniksa Pharmaceuticals by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company's stock worth $4,827,000 after acquiring an additional 4,361 shares during the period. New York State Common Retirement Fund lifted its holdings in Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock valued at $302,000 after purchasing an additional 1,680 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $258,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KNSA has been the topic of a number of research reports. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price on the stock. Finally, Wedbush reiterated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has an average rating of "Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Stock Up 0.8%

KNSA traded up $0.21 during trading on Friday, reaching $27.39. The company's stock had a trading volume of 49,171 shares, compared to its average volume of 608,073. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -195.49 and a beta of 0.07. The firm has a fifty day simple moving average of $23.54 and a two-hundred day simple moving average of $21.61. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $17.38 and a 1 year high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same quarter last year, the firm earned ($0.25) EPS. The firm's revenue for the quarter was up 72.5% on a year-over-year basis. As a group, equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 36,372 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total value of $809,277.00. Following the sale, the chief financial officer now owns 22,958 shares of the company's stock, valued at $510,815.50. This represents a 61.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael R. Megna sold 9,051 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the transaction, the chief accounting officer now directly owns 26,528 shares of the company's stock, valued at approximately $595,553.60. This trade represents a 25.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 329,910 shares of company stock valued at $8,336,038. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.